Related Experiment Video
Updated: Aug 30, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Novel agents for chemoprevention, screening methods, and sampling issues
Mary Jo Fackler1, Ella Evron, Seema A Khan
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA.
Abstract:
An aggressive approach to breast cancer control based on preventing the disease must complement efforts at effective treatment. To date clinical trials testing new chemopreventative agents have not generally met with the kind of success expected. A wide range of new breast cancer chemopreventative agents are poised to be tested in clinical trials. We review these novel agents and approaches, including those for which clinical trials have been initiated and those that are promising in the preclinical arena. Further progress in this area requires not only new agents, but novel methods for screening for risk assessment, sampling and development of intermediate biomarkers. We review these novel potential surrogate endpoints, including new imaging-techniques, breast sampling approaches, and methods to assess biomarkers in breast epithelium. Factors that could contribute to a meaningful choice of the chemopreventive agents and the design of clinical trials are discussed.
Insights
Preventing breast cancer requires novel chemopreventive agents and improved risk assessment methods. This review covers promising agents and new biomarkers for future clinical trials.
Area of Science:
- Oncology
- Preventive Medicine
- Biomarker Research
Background:
- Effective breast cancer control necessitates a dual approach of prevention and treatment.
- Current clinical trials for chemopreventive agents have yielded limited success.
- Numerous novel breast cancer chemopreventive agents are under development for clinical trials.
Purpose of the Study:
- To review novel breast cancer chemopreventive agents and approaches.
- To discuss advancements in risk assessment, sampling, and biomarker development.
- To explore factors influencing the selection of chemopreventive agents and clinical trial design.
Main Methods:
- Review of existing literature on breast cancer chemoprevention.
- Identification of agents currently in clinical trials or preclinical development.
- Analysis of novel methods for risk assessment and biomarker identification.
Main Results:
- A range of new chemopreventive agents are progressing towards clinical trials.
- Novel imaging techniques and breast sampling methods show promise for risk assessment.
- Development of intermediate biomarkers is crucial for future progress.
Conclusions:
- Advancing breast cancer prevention requires both new chemopreventive agents and innovative trial methodologies.
- Improved risk stratification and surrogate endpoints are essential for successful clinical trials.
- A comprehensive strategy integrating novel agents, biomarkers, and trial designs is needed for effective breast cancer control.
More Related Videos
Related Concept Videos
02:59Cancer Prevention
Some...
01:25Mutagenicity and Carcinogenicity